Table 2.
Overview of the medical literature regarding anti-interleukin-1 therapies in the monogenic autoinflammatory disorders.
| FMF | TRAPS | MKD | CAPS | PAPAs | MAJEEDs | BS | |
|---|---|---|---|---|---|---|---|
| Anakinra | [44–58] | [59] [60–64] |
[65–72] | [73] [74–94] |
[95–100] | [38] | [101, 102] |
|
| |||||||
| Canakinumab | [46, 50] [58, 103, 104] |
[105–107] | [68] | [93, 94, 108–116] | [117] | [38] | [118] |
|
| |||||||
| Rilonacept | [50] [119–121] |
[122–128] | |||||
BS: Blau syndrome; CAPS: cryopyrin-associated periodic syndromes; FMF: familial Mediterranean fever; MAJEEDs: Majeed syndrome; MKD: mevalonate kinase deficiency syndrome; PAPAs: pyogenic arthritis-pyoderma gangrenosum-acne syndrome; TRAPS: tumor necrosis factor receptor-associated periodic syndrome.